Edesa Biotech, Inc. (EDSA): Price and Financial Metrics
EDSA Price/Volume Stats
|Current price||$0.63||52-week high||$2.81|
|Prev. close||$0.72||52-week low||$0.51|
|Day high||$0.72||Avg. volume||119,002|
|50-day MA||$0.85||Dividend yield||N/A|
|200-day MA||$1.12||Market Cap||13.33M|
EDSA Stock Price Chart Interactive Chart >
Edesa Biotech, Inc. (EDSA) Company Bio
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
EDSA Latest News Stream
|Loading, please wait...|
EDSA Latest Social Stream
View Full EDSA Social Stream
Latest EDSA News From Around the Web
Below are the latest news stories about EDESA BIOTECH INC that investors may wish to consider to help them evaluate EDSA as an investment opportunity.
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update In Vitro Study Shows EB05 Effective Against Multiple Pathogens In June 2023, Edesa Biotech, Inc. (NASDAQ:EDSA) announced positive results from an in vitro study investigating EB05 (paridiprubart) against a panel of respiratory pathogens ( Malty et al., 2023 ). EB05 is an inhibitor of Toll-like receptor 4 (TLR4)
Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2023 and provided an update on its business.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the Canaccord Genuity 43rd Annual Growth Conference being held in Boston from August 7-10, 2023.
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!
EDSA Price Returns